Competitive Intelligence · US MASH
From question to answer in five steps. Read the full analysis →
- Module
- Competitive Intelligence
- Indication
- Metabolic Dysfunction-Associated Steatohepatitis
- Market
- United States
- Stage
- In-Market
- Decision
- Who controls the US MASH market and how should Rezdiffra defend access against in-market semaglutide?
Sources: FDA · NEJM · ClinicalTrials.gov · JAMA Network Open
- Rezdiffra (resmetirom) — FDA accelerated approval Mar 14, 2024 for noncirrhotic NASH with…
- Wegovy (semaglutide 2.4 mg) — FDA accelerated approval Aug 15, 2025 for noncirrhotic MASH…
- MAESTRO-NASH — resmetirom MASH resolution 25.9%/29.9% (80/100mg) vs 9.7% placebo.
- ESSENCE — semaglutide MASH resolution 62.9% vs 34.3%.
8 source checks on this analysis · each cites the document it came from
US MASH competitive set — approved agents and key Phase 3 pipeline
| Agent (company) | Class / MOA | US status |
|---|---|---|
| Rezdiffra (resmetirom) — Madrigal | Oral THR-β agonist | Approved Mar 14, 2024 (accelerated; NDA217785) |
| Wegovy (semaglutide 2.4 mg) — Novo Nordisk | GLP-1 receptor agonist (injectable) | Approved Aug 15, 2025 (accelerated) |
| Lanifibranor — Inventiva | Pan-PPAR (α/δ/γ) agonist | Phase 3 (pre-approval) |
- The duopoly is live: corrected competitive status
- Head-to-head clinical positioning
- US payer architecture & the access defense
- The IRA price-negotiation clock
- Pipeline & emerging white space
- The US diagnosis funnel & share-leakage levers
The US MASH market is a live two-drug duopoly: Rezdiffra (resmetirom, approved Mar 2024) and Wegovy (semaglutide 2.4 mg, approved Aug 2025) both hold accelerated approval for noncirrhotic F2-F3 MASH. Semaglutide is already in-market, not a 2027 entrant, so the defensible move is locking preferred payer access and the fibrosis-regression position now, in a Year 0-1 retention fight.
Reviewed by a MoatRx consultant before release
KOL Mapping · Saudi Arabia HR+/HER2- breast cancer
Opened 2026-09-20. The brief's own pages follow, with every clinician name, identifier and institution replaced. Pages about an individual are never shown.
- Module
- KOL Mapping
- Indication
- HR+/HER2- breast cancer
- Market
- Saudi Arabia
- Buyer
- Medical affairs lead, Saudi Arabia, breast cancer
- Publications20
- Congresses20
- Treatment guidelines20
- Clinical trials20
- Societies10
- Editorial boards10
558 records cleared · 47 set aside
A record counts only if its source was opened and matched to the clinician, who must hold a treating specialty and no company affiliation. Records that fail are set aside with the reason recorded.
9 T1
16 T2
294 Below the bar
319 clinicians found. Names appear only in the deliverable.
